{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-075260","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.952172+00:00","generated_at":"2026-06-17T22:28:33.861176+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coya reports positive proof-of-concept data for COYA 302 in ALS; Treg function up, biomarkers down, ALSFRS stable","bullets":["Treatment with IL-2/CTLA4-Ig (COYA 302) over 48 weeks significantly increased Treg suppressive function and Treg numbers in 4 ALS patients.","Biomarkers of oxidative stress (4-HNE, ox-LDL) were reduced; mean ALSFRS-R scores not statistically different from baseline, suggesting disease stabilization.","Adverse events limited to mild injection site reactions; no deaths or serious AEs; all 4 patients completed the study.","Study is open-label, single-arm, proof-of-concept; data supports further development of COYA 302 for ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-075260","json":"https://secwatch.observer/filing/0001193125-23-075260.json","markdown":"https://secwatch.observer/filing/0001193125-23-075260.md","text":"https://secwatch.observer/filing/0001193125-23-075260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523075260/0001193125-23-075260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523075260/d464304d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:28:33.861176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}